I.V. administration may produce initial increase in blood glucose concentrations in insulinoma; however, insulinoma may release insulin and secondary hypoglycemia may occur. Glucagon (rDNA origin) contraindicated in insulinoma. Use contraindicated in known pheochromocytoma. Hypersensitivity reactions possible. Allergic reactions, including rash, urticaria, respiratory distress, and rarely, hypotension and anaphylaxis with respiratory distress reported. Use with caution in conditions associated with reduced concentrations of releasable glucose in liver (e.g. prolonged fasting, starvation, adrenal insufficiency, chronic hypoglycemia). Use with caution in diabetes. Possible tachycardia and hypertension. Use with caution to inhibit GI motility in geriatric patients with known cardiac disease. Use with caution in adrenal insufficiency, chronic hypoglycemia, prolonged fasting and/or starvation (levels of glucose stores in liver may be decreased). May contain lactose (avoid administration in hereditary galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption).